Leerink Swann Weighs in on Endo International plc -‘s FY2017 Earnings (ENDP)
Endo International plc – (NASDAQ:ENDP) (TSE:ENL) – Leerink Swann issued their FY2017 EPS estimates for shares of Endo International in a research note issued to investors on Tuesday, according to Zacks Investment Research. Leerink Swann analyst A. Fadia expects that the company will post earnings per share of $3.65 for the year. Leerink Swann currently has a “Outperform” rating and a $12.00 price target on the stock. Leerink Swann also issued estimates for Endo International’s Q4 2017 earnings at $0.57 EPS, Q1 2018 earnings at $0.72 EPS, Q2 2018 earnings at $0.79 EPS, FY2018 earnings at $3.02 EPS, FY2019 earnings at $3.20 EPS, FY2020 earnings at $2.92 EPS and FY2021 earnings at $2.73 EPS.
Other analysts have also recently issued research reports about the stock. Mizuho reissued a “buy” rating on shares of Endo International in a research report on Friday, November 10th. Zacks Investment Research raised shares of Endo International from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a research report on Wednesday, October 11th. ValuEngine raised shares of Endo International from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Vetr cut shares of Endo International from a “strong-buy” rating to a “buy” rating and set a $8.92 price target on the stock. in a research report on Monday, December 18th. Finally, Cantor Fitzgerald set a $9.00 price target on shares of Endo International and gave the stock a “hold” rating in a research report on Monday, October 30th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Endo International has a consensus rating of “Hold” and a consensus target price of $10.79.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to analyst estimates of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. Endo International’s revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.01 earnings per share.
Large investors have recently modified their holdings of the stock. Blair William & Co. IL acquired a new stake in Endo International in the second quarter valued at approximately $126,000. Oakbrook Investments LLC acquired a new stake in Endo International in the fourth quarter valued at approximately $133,000. LMR Partners LLP acquired a new stake in Endo International during the third quarter worth approximately $148,000. Riverhead Capital Management LLC raised its holdings in Endo International by 64.4% during the second quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares in the last quarter. Finally, Bank of Hawaii acquired a new stake in Endo International during the second quarter worth approximately $180,000. 93.10% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.mareainformativa.com/leerink-swann-weighs-in-on-endo-international-plc-s-fy2017-earnings-endp-updated-updated-updated/125600/.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.